Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. (TMO)
Overview
Thermo Fisher Scientific Inc. is the world's largest life sciences and laboratory tools company, serving pharmaceutical, biotechnology, academic, government, and clinical customers with instruments, consumables, diagnostics, and outsourced research and manufacturing services. Founded in 1956 (through the merger that created Thermo Electron, later combined with Fisher Scientific in 2006) and headquartered in Waltham, Massachusetts, Thermo Fisher is classified within the Healthcare sector under Diagnostics & Research. The company employs approximately 125,000 people globally and generated roughly $44.6 billion in revenue in fiscal 2025 (up about 4% year-over-year), with trailing-twelve-month revenue closer to $46 billion and accelerating growth (10% year-over-year, 5% organic) in more recent quarters. With a market capitalization above $225 billion, Thermo Fisher is one of the largest companies serving the "life sciences tools" industry — effectively supplying the picks and shovels of biomedical research, drug development, and clinical diagnostics worldwide.
What They Do & How They Make Money
Thermo Fisher makes money by selling an enormous and diversified catalog of scientific instruments, reagents, consumables, software, and outsourced services to essentially every organization involved in biomedical research, drug discovery and manufacturing, and clinical diagnosis. Its customers include pharmaceutical and biotech companies developing new drugs, academic and government research labs, hospitals and clinical laboratories running diagnostic tests, and industrial/environmental testing labs. Revenue comes from several interlocking business models: selling durable scientific instruments (mass spectrometers, gene sequencers, PCR/thermal cycler systems, electron microscopes) that create long-term platforms; selling high-margin, recurring consumables and reagents that customers must continually repurchase to run those instruments (a classic "razor and blades" dynamic that generates durable, repeat revenue); providing diagnostic test kits and systems used by hospitals and clinical labs to detect infections, allergies, and other conditions; and, increasingly, providing outsourced pharma services — contract development and manufacturing (CDMO) for biologics and drug substances, and clinical research services — where Thermo Fisher is paid to help pharmaceutical companies develop, test, and manufacture their drugs and vaccines rather than the customer doing so in-house. This services business has become a major growth engine, reinforced by Thermo Fisher's 2025 agreement to acquire Clario, a clinical research/clinical trial technology company, for roughly $9.4 billion, while the company simultaneously divested its lower-growth microbiology testing business (sold to Astorg for about $1.075 billion in 2026) to sharpen its focus on higher-margin, faster-growing services.
Business Segments
Thermo Fisher reports results across four segments, per its 10-K filings and recent quarterly disclosures (Q2 2026 quarterly revenue shown for scale):
- Laboratory Products and Biopharma Services (~$6.7 billion quarterly, the largest segment) — Laboratory equipment, consumables, and the "research and safety market channel" (essentially a distribution business selling a huge range of lab products), combined with pharma services including contract drug manufacturing (CDMO) and clinical research services — the segment most affected by the pending Clario acquisition and a key growth driver.
- Life Sciences Solutions (~$2.8 billion quarterly) — Reagents, instruments, and consumables for biological and medical research, including tools used in drug and vaccine discovery/production and in diagnosing infections and diseases (e.g., genetic analysis, cell culture, and bioproduction reagents).
- Analytical Instruments (~$1.85 billion quarterly) — Instruments, consumables, software, and services (chromatography, mass spectrometry, electron microscopy, and related analytical technologies) sold to pharmaceutical, biotech, academic, government, environmental, industrial, and clinical laboratory customers.
- Specialty Diagnostics (~$1.2 billion quarterly) — Clinical diagnostic products including immunodiagnostic test kits, allergy and autoimmune blood-test systems, transplant diagnostics, and (until its 2026 divestiture) microbiology culture media and antimicrobial susceptibility testing, along with healthcare distribution services.
Laboratory Products and Biopharma Services is by far the largest segment by revenue, reflecting both the breadth of Thermo Fisher's product distribution business and its growing outsourced pharma services arm.
Competitors
Thermo Fisher operates in a large, fragmented life sciences tools and diagnostics industry with competition varying by product category:
- Broad life sciences tools/diagnostics peers: Danaher Corporation is Thermo Fisher's closest large-scale competitor, with a similarly diversified portfolio spanning life sciences, diagnostics, and biotechnology tools; Agilent Technologies competes closely in analytical instruments and life sciences consumables.
- Instrumentation-focused competitors: Waters Corporation and Bruker compete in analytical instruments (chromatography, mass spectrometry); Illumina is a leading competitor in genomic sequencing technology.
- Reagents/consumables competitors: Merck KGaA's MilliporeSigma life sciences business and Bio-Rad Laboratories compete in reagents, lab consumables, and bioprocessing.
- Diagnostics-focused competitors: Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Revvity (formerly PerkinElmer) compete in clinical and specialty diagnostics.
- Outsourced pharma services/CRO competitors: IQVIA Holdings, Lonza, Catalent (part of Novo Holdings), Charles River Laboratories, and other CDMOs/CROs compete with Thermo Fisher's growing pharma services and clinical research business, an area of increasing strategic focus following the Clario acquisition.
Competitive Position
Thermo Fisher's competitive moat is built on scale and breadth: it offers one of the industry's broadest integrated portfolios spanning instruments, consumables, software, and outsourced services, allowing it to serve customers across the entire research-to-commercialization workflow — a "one-stop shop" positioning that larger, well-capitalized customers value and that creates meaningful switching costs once labs standardize on its instrument platforms and reagent ecosystems. Its scale also gives it advantages in manufacturing efficiency, global distribution reach, and R&D investment capacity that smaller, specialized competitors struggle to match. The company has also been investing in AI-enabled analytical software (through recent smaller acquisitions) to strengthen its data and software offerings alongside hardware. That said, Thermo Fisher faces real headwinds: organic growth has moderated to mid-single digits in a maturing life sciences tools market, a deceleration from the exceptional growth it enjoyed during the COVID-19 pandemic (when diagnostic testing and vaccine-related demand surged); the company carries a large debt load from its acquisition-heavy growth strategy, which some analysts flag as a constraint on financial flexibility; end-market demand from biotech and pharma customers has been mixed, with funding pressures on smaller biotech firms affecting instrument capital-spending cycles; and the large pending Clario acquisition (~$9.4 billion) carries integration risk, alongside recent executive departures (COO and an EVP) that add near-term leadership transition uncertainty. Valuation has also been a point of debate among analysts, with fair-value estimates spanning a wide range. Overall, Thermo Fisher remains the largest and most diversified player in life sciences tools, with a durable instruments-plus-consumables-plus-services model, but its growth trajectory depends on successfully executing its shift toward higher-margin pharma services amid a more moderate demand environment than the pandemic-era boom years.